Radiopharma-focused company Lantheus misses Q2 estimates as competition bites

Lantheus Holdings

06/08/2025 12:09

Overview

Lantheus Q2 revenue falls 4.1%, missing analyst expectations, per LSEG data

Adjusted EPS for Q2 misses consensus, reflecting PSMA PET competition impact

Co announces $400 mln stock repurchase program, expanding radiopharmaceutical portfolio

Announced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026

Outlook

Company sees FY 2025 revenue at $1.475 bln to $1.51 bln

Lantheus expects FY 2025 adj EPS of $5.50 to $5.70

Company cites increased PSMA PET competition impacting PYLARIFY performance

Result Drivers

PSMA PET COMPETITION - Increased competition in the PSMA PET landscape impacted PYLARIFY sales, contributing to revenue decline

ACQUISITIONS - Completed acquisitions of Evergreen Theragnostics and Life Molecular Imaging to expand radiopharmaceutical portfolio

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$378 mln
$389.10 mln (13 Analysts)
Q2 Adjusted EPS
Miss
$1.57
$1.67 (12 Analysts)
Q2 EPS
$1.12
Q2 Free Cash Flow
$79.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Lantheus Holdings Inc is $130.00, about 44.1% above its August 5 closing price of $72.63

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release: ID:nGNX35Fs3C

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)